Read by QxMD icon Read

Breast cancer and fertility

Shalender Bhasin, Juan P Brito, Glenn R Cunningham, Frances J Hayes, Howard N Hodis, Alvin M Matsumoto, Peter J Snyder, Ronald S Swerdloff, Frederick C Wu, Maria A Yialamas
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence...
March 17, 2018: Journal of Clinical Endocrinology and Metabolism
Victor O Oria, Paul Lopatta, Oliver Schilling
A disintegrin and a metalloprotease (ADAM) 9 is a metzincin cell-surface protease involved in several biological processes such as myogenesis, fertilization, cell migration, inflammatory response, proliferation, and cell-cell interactions. ADAM9 has been found over-expressed in several solid tumors entities such as glioma, melanoma, prostate cancer, pancreatic ductal adenocarcinoma, gastric, breast, lung, and liver cancers. Immunohistochemical analyses highlight ADAM9 expression by actual cancer cells and associate its abundant presence with clinicopathological features such as shortened overall survival, poor tumor grade, de-differentiation, therapy resistance, and metastasis formation...
March 17, 2018: Cellular and Molecular Life Sciences: CMLS
Avi Ben-Haroush, Irit Ben-Aharon, Yechezkel Lande, Benjamin Fisch
BACKGROUND: Controlled ovarian hyperstimulation (COH) followed by oocyte retrieval is a leading option for fertility preservation before chemotherapy, yet this procedure causes excessive serum levels of estradiol (E2), which are often detrimental for cancer patients. Aromatase inhibitors are often used in breast cancer patients during COH to prevent elevated levels of E2. OBJECTIVES: To describe our experience with COH for oocyte cryopreservation in non-breast cancer patients using aromatase inhibitors...
March 2018: Israel Medical Association Journal: IMAJ
Walter Alexander
We present sessions on hepatocellular carcinoma and colorectal and pancreatic cancers from ASCO GI. Key sessions from SABCS covered dose intensification, new trial data, and ovarian suppression to preserve fertility.
March 2018: P & T: a Peer-reviewed Journal for Formulary Management
Sarah Bollinger
Triple-negative breast cancer (TNBC) is a subtype of breast cancer known to have poorer prognoses and lower survival rates compared with other types of breast cancer. In addition, TNBC is overrepresented in premenopausal African American women. Using grounded theory as the qualitative methodological approach, the present article elucidates unique biopsychosocial challenges and needs of young African American women with TNBC. A study group of six women with TNBC and a comparison group of six women with estrogen receptor-positive breast cancer were interviewed longitudinally over three time points throughout the cancer treatment trajectory...
February 22, 2018: Health & Social Work
Alejandra Recio-Saucedo, Anthony W Gilbert, Sue Gerty, Ramsey I Cutress, Diana Eccles, Claire Foster
PURPOSE: The implications of a diagnosis and consequent surgical treatment for breast cancer may be different for young women compared to older women. This study investigated the information requirements of young women to support their treatment decision making at diagnosis.
. PARTICIPANTS & SETTING: A purposeful sample of 20 women diagnosed with breast cancer aged 40 years or younger who had undergone surgery and had participated in a large cohort study in the United Kingdom...
March 1, 2018: Oncology Nursing Forum
Sebastian Findeklee
Newly diagnosed cancer in pregnancy is an issue with increasing importance, because fulfilling the wish to have a child is shifted later in life. Tumour disease is diagnosed in around 0.1% of all pregnancies in Germany. Most common tumour entities involve the breast, the cervix and the hematopoietic system. As tumour prognosis is not negatively affected by pregnancy and gestation does not disclude oncologic therapy it is important to plan treatment immediately. Oncologic surgery preserving the uterus is not at all limited...
February 1, 2018: Zeitschrift Für Geburtshilfe und Neonatologie
Hiroko Komatsu, Kaori Yagasaki, Hideko Yamauchi
OBJECTIVE: The objective of this study was to understand how reproductive-age women with breast cancer make fertility-related decisions. METHODS: Using grounded theory methodology, we collected data from 11 reproductive-age women with breast cancer between March and August 2016. Verbatim transcriptions were analyzed using constant comparative analysis and open, axial, and selective coding. RESULTS: "Fertility Decision-Making under Certainty and Uncertainty" emerged as a core category...
March 2018: Sexual & Reproductive Healthcare: Official Journal of the Swedish Association of Midwives
Dong-Yun Lee, Seul Ki Kim, Miran Kim, Kyung Joo Hwang, Seok Hyun Kim
Although the survival rate of hematologic malignancies in young patients is very high, cytotoxic therapies such as chemotherapy and total body irradiation therapy can significantly reduce a patient's reproductive capacity and cause irreversible infertility. Early ovarian failure also commonly occurs following additional cancer treatment, bone marrow transplantation, or autologous transplantation. Because the risk of early ovarian failure depends on the patient's circumstances, patients with a hematologic malignancy must consult health professionals regarding fertility preservation before undergoing treatments that can potentially damage their ovaries...
December 2017: Clinical and Experimental Reproductive Medicine
Hoon Kim, Seul Ki Kim, Jung Ryeol Lee, Kyung Joo Hwang, Chang Suk Suh, Seok Hyun Kim
With advances in the methods of cancer treatment used in modern medicine, the number of breast cancer survivors has been consistently rising. As the number of women who wish to become pregnant after being diagnosed with breast cancer increases, it is necessary to consider fertility preservation in these patients. However, medical doctors may be unaware of the importance of fertility preservation among cancer patients because most patients do not share their concerns about fertility with their doctors. Considering the time spent choosing and undergoing treatment, an early referral to a reproductive specialist is the best way to prevent a delay in cancer treatment...
December 2017: Clinical and Experimental Reproductive Medicine
L Del Pup, F A Peccatori
Very high progesterone levels (mean 186.6 ± 43.6 ng/mL) during the luteal phase were found in a small study of breast cancers patients undergoing controlled ovarian stimulation (COS) with letrozole plus recombinant FSH. Results highlight the need to further evaluate this in larger series. While waiting, the clinical significance of high progesterone levels can be drawn from epidemiological and experimental data here reviewed in order to give reassurance to the clinician involved in fertility preservation. If the progesterone increase will be confirmed, epidemiological and experimental data do not seem to indicate a detrimental effect or they could even be protective...
January 2018: European Review for Medical and Pharmacological Sciences
Ines Vaz-Luis, Ann H Partridge
Considerable controversy exists regarding the safety of elective exogenous hormonal exposure among breast cancer survivors and women at high risk of developing the disease (referred to herein as 'previvors'). We performed a qualitative analysis focused on four areas of potential exogenous exposure to hormones among previvors and survivors: hormonal contraception; systemic hormone-replacement therapy (HRT); localized HRT; and hormonal manipulation for fertility preservation or enhancement. Herein, we discuss the available data and present clinical recommendations regarding the safety of hormonal exposure for both previvors and survivors...
January 23, 2018: Nature Reviews. Clinical Oncology
Elizabeth S Constance, Molly B Moravek, Jacqueline S Jeruss
Breast cancer is the most frequently occurring cancer in women of reproductive age. Treatments for breast cancer may eliminate or diminish fertility, making discussions about fertility preservation essential prior to initiation of gonadotoxic therapies. Additionally, even in patients who do not require chemotherapy, the use of adjuvant endocrine therapy will often push patients out of the reproductive window before treatment is completed. The only established methods for fertility preservation are oocyte or embryo cryopreservation, but experimental methods, such as ovarian suppression with GnRH agonists and ovarian tissue cryopreservation, show great promise...
2018: Cancer Treatment and Research
Michaël Grynberg, Jade Raad, Marjorie Comtet, Claire Vinolas, Isabelle Cédrin-Durnerin, Charlotte Sonigo
BRCA 1 and 2 genes play a critical role in the safeguarding of DNA integrity. It is now well established that BRCA1 and BRCA2-mutated women are at increased risk of breast and ovarian cancers. However, several lines of evidence indicate that this genetic status may also be associated with ovarian dysfunction, in particular a reduced ovarian reserve. Considering the gonadal toxicity of cancer treatments and the recommendation of prophylactic bilateral salpingo-oophorectomy around 40 years, young BRCA mutation carriers are confronted with difficult family planning decisions...
February 2018: Future Oncology
William D Winkelman, Mitchell P Rosen, Evelyn Mok-Lin
OBJECTIVE: To study the resources available for cancer patients once referred for fertility preservation. MATERIALS AND METHODS: Cross-sectional study clinics that are members of the Society for Assisted Reproductive Technology assess support for fertility preservation. RESULTS: Surveys were distributed to a total of 1135 members at 394 Society for Assisted Reproductive Technology clinics. Responses were received from 99 individuals representing a total of 84 unique clinics (21...
January 8, 2018: American Journal of Clinical Oncology
Katarzyna Pogoda, Agnieszka Jagiełło-Gruszfeld, Anna Niwińska, Maria Litwiniuk, Jakub Rzepka, Zbigniew Nowecki
No abstract text is available yet for this article.
January 9, 2018: Journal of Adolescent and Young Adult Oncology
Tomoko Hashimoto, Yusuke Nakamura, Ryuichiro Obata, Masakazu Doshida, Mayumi Toya, Takumi Takeuchi, Koichi Kyono
Purpose: To assess the efficacy of fertility preservation (FP) and the impact of chemotherapy on the reproductive potential of Japanese patients with breast cancer. Methods: Sixty-two patients with breast cancer visited the authors' centers from October, 2003 to June, 2015. They were divided into two groups according to the treatment: oocyte or embryo vitrification for FP before cancer treatment (group A) or infertility treatment after cancer treatment (group B)...
October 2017: Reproductive Medicine and Biology
Tuomo Meretoja, Hanna Ihalainen, Marjut Leidenius
Breast inflammation, i.e. mastitis is an entity with a variable etiology and severity, typically affecting women of fertile age. In most cases, anamnesis reveals the etiology of the disease, bacterial puerperal mastitis associated with breastfeeding being the most common. Periductal mastitis is a breast inflammation typically associated with smoking in women of 40 to 50 years of age, localized to the region of the areola. Granulomatous mastitis and other rare breast inflammations usually require specialized care...
2017: Duodecim; Lääketieteellinen Aikakauskirja
O Basso, C R Weinberg, A A D'Aloisio, D P Sandler
STUDY QUESTION: Does maternal age at a daughter's birth predict her subsequent probability of lifelong childlessness? SUMMARY ANSWER: In this study population, women born to older mothers were more likely to be childless. WHAT IS KNOWN ALREADY: Although maternal age at childbearing is increasing in many countries, there is limited evidence on whether being born to older parents may influence offspring fertility. STUDY DESIGN SIZE AND DURATION: This analysis included 43 135 women from the US-based Sister Study, a cohort study of 50 884 sisters of women with breast cancer recruited between 2003 and 2009...
February 1, 2018: Human Reproduction
Fedro Alessandro Peccatori, Giorgia Mangili, Alice Bergamini, Francesca Filippi, Fabio Martinelli, Federica Ferrari, Stefania Noli, Emanuela Rabaiotti, Massimo Candiani, Edgardo Somigliana
Fertility issues have become critical in the management and counseling of BRCA mutation carriers. In this setting four points deserve consideration. (1) Women in general lose their ability to conceive at a mean age of 41 years, thus the suggested policy of prophylactic bilateral salpingo-oophorectomy at age 40 for BRCA mutation carriers does not affect the chances of natural pregnancy. Conversely, if the procedure is chosen at 35 years old, oocyte cryopreservation prior to surgery should be considered. (2) Some evidence suggests that ovarian reserve may actually be partly reduced in BRCA mutations carriers and that the mutation may affect ovarian responsiveness to stimulation...
February 1, 2018: Human Reproduction
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"